Aliphatic and aromatic oxidations, epoxidation and s-oxidation of prodrugs that yield active drug metabolites

Current Medicinal Chemistry

Volumn 18, Issue 32, 2011, Pages 4885-4900

  Tekes, K ^a   Kalasz H ^a,b   Hasan, M Y ^b   Adeghate, E ^b   Darvas, F ^c   Ram, N ^a   Adem, A ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^c ComInnex Ltd ^*  (Hungary)

Author keywords

Active metabolites; Aliphatic oxidation; Aromatic oxidation; Cytochrome P450; Drugs; Epoxidation; Hydroxylation; Lipophilicity; LogP; Metabolism; S oxidation; Total polar surface area

Indexed keywords

2 OXOTICLOPIDINE; 5 HYDROXYMETHYL TOLTERODINE; ALIPHATIC COMPOUND; AROMATIC COMPOUND; BETA HYDROXYSIMVASTATIN; BUSPIRONE; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DRUG METABOLITE; FLUTAMIDE; GLIMEPIRIDE; HYDROXYZINE; IFOSFAMIDE; ISOTRETINOIN; ITRACONAZOLE; LOSARTAN; METRONIDAZOLE; NABUMETONE; NALIDIXIC ACID; NORTRIPTYLINE; PALIPERIDONE; PHENOBARBITAL; PRIMIDONE; QUINIDINE; RISPERIDONE; SIMVASTATIN; TERFENADINE; TICLOPIDINE; TOLTERODINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE; ALOPECIA; AMEBIASIS; ANALYTIC METHOD; ARTICLE; ATYPICAL DEPRESSION; CHEMISTRY; CHRONIC BRONCHITIS; CHRONIC URTICARIA; COMMUNITY ACQUIRED PNEUMONIA; CONVULSION; DEPRESSION; DERMATITIS; DRUG EFFECT; DRUG METABOLISM; DRUG TRANSFORMATION; DYSTHYMIA; ENZYME METABOLISM; EPOXIDATION; GENERALIZED ANXIETY DISORDER; GIARDIASIS; HEART ARRHYTHMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEUKEMIA; LIPOPHILICITY; LYMPHOMA; MEDICINAL PLANT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION KINETICS; PEPTIC ULCER; PHARMACOLOGY; PHYTOCHEMISTRY; PROSTATE CANCER; PRURITUS; S OXIDATION; SCHIZOPHRENIA; SINUSITIS; STRUCTURE ACTIVITY RELATION; TRICHOMONIASIS;

CHEMISTRY, PHARMACEUTICAL; EPOXY COMPOUNDS; HUMANS; HYDROXYLATION; MODELS, CHEMICAL; OXIDATION-REDUCTION; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PRODRUGS;

EID: 80054854768     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711797535227     Document Type: Article

References (86)

1. Smith, F.T.; Clark, R. Prodrugs and Drug Latentiation, in Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry, 11th Edition, Block, J.H.; Beale, J.M. (Eds,), Lippincott William & Wilkins, Philadelphia, 2003.
2. Chuang, S.S.; Helvig, C.; Taimi, M.; Ramshaw, H.A.; Collop, A.H.; Amad, M.; White, J.A.; Petkovich, M.; Jones. G.; Korczak, B. CYP2U1, a novel human thymus and brain specific cytochrome P450, catalyzes omega and (omega 1) hydroxylation of fatty acids. J. Biol. Chem., 2004, 279, 6305-6314. (Pubitemid 38248763)
3. Voegtlin, C.; Smith, H.W. Quantitative studies in chemotherapy III. The oxidation of arsphenamine. J. Pharmacol. Exp. Ther., 1920, 16, 199-217.
4. Guroff, G.D.J.; Jerina, D.M.; Renson, J.; Witkop, B.; Udenfriend, S. Hydroxylation induced migration: The NIH shift. Recent experiments reveal an unexpected and general result of enzymatic hydroxylation of aromatic compounds. Science, 1967, 157, 1524-1530.
5. Kalgutkar, A.S.; Soglia, J.R. Minimising the potential for metabolic activation in drug discovery. Expert Opin. Drug Metab. Toxicol., 2005, 1, 91-142.
6. Prueksaritanont, T.; Lin, J.H.; Baillie, T. Complicating factors in safety testing of drug metabolites: Kinetic differences between generated and preformed metabolites. Toxicol. Appl. Pharmacol., 2006, 217, 143-152. (Pubitemid 44780764)
7. Prueksaritanont, T.; Subramanian, R.; Fang, X.; Ma, B.; Qiu, Y.; Lin, J.H.; Pearson, P.G.; Baillie TA.Glucuronidation of statins in animals and humans: A novel mechanism of statin lactonization. Drug Metab. Dispos., 2002, 30, 505-512. (Pubitemid 34456970)
8. Hochman, J.H.; Pudvah, N.T.; Qiu, Y.; Yamazaki, M.; Tang, C.; Lin, J.H.; Prueksaritanont, T. Interactions of human P glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm. Res., 2004, 21, 1688-1693.
9. Guidance for Industry on Safety testing of Drug Metabolites" issued in 2008 by Food and Drug Administration (FDA).
10. Tiseo, P.J.; Thaler, H.T.; Lapin, J.; Inturrisi, C.E.; Portenoy, R.K.; Foley, K.M. Morphine-6-glucuronide concentrations and opioid-related side effects: A survey in cancer patients. Pain, 1995, 61, 47-54.
11. Pasternak GW, Bodnar RJ, Clark JA, Inturrisi CE. Morphine-6-glucuronide, a potent mu agonist. Life Sci 1987;41:2845-2849. (Pubitemid 17165867)
12. Sinkula, A.A.; Morozowich, W.; Rowe, E.L. Chemical modification of clindamycin: Synthesis and evaluation of selected esters. J. Pharm. Sci., 1973, 62, 1106-1111.
13. Hemenway, J.N.; Jarho, P.; Henri, J.T.; Nair, S.K.; Vander-Velde, D.; Georg, G.I.; Stella, V.J. Preparation and physicochemical characterization of a novel water-soluble prodrug of carbamazepine. J. Pharm. Sci., 2010, 99, 1810-1825.
14. Coleman, M.D. Human Drug Metabolism, An Introduction, 2nd ed. Wile-Blackwell, Chichester, 2010.
15. Martino, R.; Gilard, V.; Desmoulin, F.; Malet-Martino, M. Fluorine 19 or phosphorus 31 NMR spectroscopy: A suitable analytical technique for quantitative in vitro metabolic studies of fluorinated or phosphorylated drugs. J. Pharm. Biomed. Anal., 2005, 38, 871-891. (Pubitemid 41115794)
16. www.drugbank.ca
17. http://www.accessmedicine.com/popup.aspx?aID=959800
18. Odontiadis, J.; Franklin, M. Simultaneous quantitation of buspirone and its major metabolite 1-(2-pyrimidinyl)piperazine in human plasma by highperformance liquid chromatography with coulometric detection. J. Pharm. Biomed. Anal., 1996, 14, 347-351. (Pubitemid 26155323)
19. Rodvold, K.A. Clinical pharmacokinetics of clarithromycin. Clin. Pharmacokin. 1999, 37, 385-398.
20. Rodrigues, A.D.; Roberts, E.M.; Mulford, D.J.; Yao, Y.; Quellete, D. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab. Dispos., 1997, 25, 623-630. (Pubitemid 27213105)
21. Wibawa, J.I.D.; Shaw, P.N.; Barrett, D.A. Quantification of clarithromycin, its 14-hydroxy and decladinose metabolites in rat plasma, gastric juice and gastric tissue using high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B, 2003, 783, 359-366. (Pubitemid 35447986)
22. Xie, H.J.; Yasar, U.; Lundgren, S.; Griskevicius, L.; Terelius, Y.; Hassan, M.; Rane, A. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J., 2003, 3, 53-61. (Pubitemid 36432466)
23. Griskevicius, L.; Yasar, U.; Sandberg, M.; Hidestrand, M.; Eliasson, E.; Tybring, G.; Hassan, M.; Dahl, M.L. Bioactivation of cyclophosphamide: The role of polymorphic CYP2C enzymes. Eur. J. Clin. Pharmacol., 2003, 59, 103-109. (Pubitemid 36793721)
24. Baumann, F.; Lorenz, C.; Jaehde, U.; Preiss, R. Determination of cyclophosphamide and its metabolites in human plasma by high-performance liquid chromatography-mass spectrometry. J. Chromatogr. B, 1999, 729, 297-305. (Pubitemid 29264136)
25. Niopas, I.; Daftsios, A.C. Determination of 2-hydroxyflutamide in human plasma by high-performance liquid chromatography and its application to pharmacokinetic studies. J. Chromatogr. B, 2001, 759, 179-183. (Pubitemid 32595451)
26. Badian, M.; Korn, A.; Lehr, K.H.; Malerczyk, V.; Waldhäusl, W. Absolute bioavailability of glimepiride (Amaryl) after oral administration. Drug Metabol. Drug Interact., 1994, 11, 331-339.
27. Ahmad Khan, M.A.; Sinha, S.; Vartak, S.; Bhartiya, A.; Kumar, S. LC determination of glimepiride and its related impurities. J. Pharm. Biomed. Anal., 2005, 39, 928-943. (Pubitemid 41441721)
28. Gurjar, M.K.; Joshi, R.A.; Chaudhuri, S.R.; Joshi, S.V.; Barde, A.R.; Gediya, L.K.; Ranade, P.V.; Kadam, S.M.; Naik, S.J. Total synthesis of cis and transhydroxyglimepiride: Active metabolite of glimepiride. Tetrahedron Lett., 2003, 44, 4853-4855. (Pubitemid 36694252)
29. Haji-Momenian, S.; Rieger, J.M.; Macdonald, T.L.; Brown, M.L. Comparative molecular field analysis and QSAR on substrates binding to cytochrome P450 2D6. Bioorg. Med. Chem., 2003, 11, 5545-5554. (Pubitemid 37464682)
30. Nicolas, J.M.; Whomsley, R.; Collart, P.; Roba, J. In vitro inhibition of human liver drug metabolizing enzymes by second generation antihistamines. Chem. Biol. Interact., 1999, 123, 63-79. (Pubitemid 29505250)
31. Péhourcq, F. A simple high-performance liquid chromatographic method for detection of hydroxyzine in human plasma after overdose. J. Pharm. Toxicol. Meth., 2004, 50, 41-44. (Pubitemid 38845000)
32. Ma, M.; Feng, F.; Sheng, Y.; Cui, S.; Liu H. Development and evaluation of an efficient HPLC/MS/MS method for the simultaneous determination of pseudoephedrine and cetirizine in human plasma: Application to Phase-I pharmacokinetic study. J. Chromatogr. B, 2007, 846, 105-111. (Pubitemid 46149498)
33. Preiss, R.; Schmidt, R.; Baumann, F.; Hanschmann, H.; Hauss, J.; Geissler, F.; Pahlig, H.; Ratzewiss, B. Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto-and carboxyifosfamide. J. Cancer Res. Clin. Oncol., 2002, 128, 385-392. (Pubitemid 34824181)
34. Chen, L.; Waxman, D.J. Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr. Pharm. Des., 2002, 8, 1405-1416. (Pubitemid 34591355)
35. Crommentuyn, K.M.L.; Schellens, J.H.M.; van den Berg, J.D.; Beijnen, J.H. In-vitro metabolism of anti-cancer drugs, methods and applications: Paclitaxel, docetaxel, tamoxifen and ifosfamide. Cancer Treatm. Rev., 1998, 24, 345-366. (Pubitemid 28537770)
36. Buggé, C.J.L.; Rodriguez, L.C.; Vane, F.M. Determination of isotretinoin or etretinate and their major metabolites in human blood by reversed-phase high-performance liquid chromatography. J. Pharm.Biomed. Anal., 1985, 3, 269-277. (Pubitemid 15020876)
37. Heykants, J.; Michiels, M,; The pharmacokinetics of itraconazol in animals and man. An overwiev. In Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. Fromtling, R.A. (Ed). Prous Science Publisher, Barcelona, 1987, pp. 223-249.
38. Li, Z.; Wang, G, Wang L.S.; Zhang, W.; Tan, Z.R.; Fan, L.; Chen, B.L.; Li, Q.; Liu, J.; Tu, J.H.; Hu, D.L.; Liu, Z.Q.; Zhou, H.H. Effects of the CYP2C913 allele on the pharmacokinetics of losartan in healthy male subjects. Xenobiotica, 2009, 39, 788-793.
39. Zhou, S.F.; Zhou, Z.W.; Huang, M. Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology, 2010, 278, 165-188.
40. Farthing, D.; Sica, D.; Fakhry, I.; Pedro, A.; Gehr, T.W.B. Simple highperformance liquid chromatographic method for determination of losartan and E-3174 metabolite in human plasma, urine and dialysate. J. Chromatogr. B, 1997, 704, 374-378. (Pubitemid 28021926)
41. Cerdá, J.M.V.; Almiñana, M.A.; Guinot, J.N.; Sanjuán, V.M.; Sanchís J.L.S. Farmacocinética del metronidazol y la gentamicina en dosis única preoperatoria para profilaxis antibiótica quirúrgica en cirugía colorrectal. Farmac. Hosp., 2008, 32, 77-82.
42. Turpeinen, M.; Hofmann, U.; Klein, K.; Mürdter, T.; Schwab, M.; Zanger, U.M. A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes. Drug Metab. Dispos., 2009, 37, 1017-1024.
43. Nobilis, M.; Kopeckž, J.; Kvetina, J.; Svoboda, Z.; Pour, M.; Kunes, J.; Holcapek, M.; Kolárová, L. Comparative biotransformation and disposition studies of nabumetone in humans and minipigs using high-performance liquid chromatography with ultraviolet, fluorescence and mass spectrometric detection. J. Pharm. Biomed. Anal., 2003, 32, 641-656. (Pubitemid 36951944)
44. Cuisinaud, G.; Ferry, N.; Seccia, M.; Bernard, N.; Sassard, J. Determination of nalidixic acid and its two major metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography. J. Chromatogr., 1980, 181, 399-406. (Pubitemid 10074748)
45. Ulrich, S.; Isensee, T.; Pester, U. Simultaneous determination of amitriptyline, nortriptyline and four hydroxylated metabolites in serum by capillary gas-liquid chromatography with nitrogen-phosphorus-selective detection. J. Chromatogr. B, 1996, 685, 81-89. (Pubitemid 26371118)
46. Tybring, G.; Nordin, J.; Widén, J. High-performance liquid chromatography-mass spectrometry for the quantification of nortriptyline and 10-hydroxynortriptyline in plasma. J. Chromatogr. B, 1998, 716, 382-386. (Pubitemid 28464587)
47. Alvin, J.; Goh, E.; Bush, M.T. Study of the hepatic metabolism of primidone by improved methodology. J. Pharmacol. Exp. Sci., 1975, 194, 117-125.
48. Ferranti, V.; Chabenat, C.; Ménager, S.; Lafont, O. Simultaneous determination of primidone and its three major metabolites in rat urine by high-performance liquid chromatography using solid-phase extraction. J. Chromatogr., 1998, 718, 199-204. (Pubitemid 28477593)
49. Brøsen, K.; Davidsen, F.; Gram, L.F. Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man. Br. J. Clin. Pharmacol., 1990 29, 248-253. (Pubitemid 20131426)
50. Guengerich, F.P.; Muller-Enoch, D.; Blair, I.A. Oxidation of quinidine by human liver cytochrome P-450. Mol. Pharmacol., 1986, 30, 287-295. (Pubitemid 16018853)
51. Bhoopathy, S.; Sarkar, M.A.; Karne, H.T. Characterization of quinidine 3-hydroxylation as a probe for the CYP 3A enzyme using a novel capillary electrophoresis technique. Eur. J. Pharm. Sci., 2002, 16, 265-272.
52. Avenoso, A.; Facciolá, G.; Salemi, M.; Spina, E. Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection. J. Chromatogr. B, 2000, 746, 173-181. (Pubitemid 30657933)
53. Fiegenbaum, M.; da Silveira, F.R.; Van der Sand, C.R.; Van der Sand, L.C.; Ferreira, M.E.; Pires, R.C.; Hutz, M.H. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin. Pharmacol. Ther., 2005, 78, 551-558. (Pubitemid 41698910)
54. Barrett, B.; Huclová, J.; Božek-Dohalskž, V.; Nmec, B.; Jelínek, I. Validated HPLC-MS/MS method for simultaneous determination of simvastatin and simvastatin hydroxy acid in human plasma. J. Pharm. Biomed. Anal., 2006, 41, 517-526.
55. Lappin, G.; Shishikura, Y.; Jochemsen, R.; Weaver, R.J.; Gesson, C.; Houston, B.; Oosterhuis, B.; Bjerrum, O.J.; Rowland, M.; Garner, C. Pharmacokinetics of fexofenadine: Evaluation of a microdose and assessment of absolute oral bioavailability. Eur. J. Pharm. Sci., 2010, 40, 125-131.
56. Yoneda, K.; Iwamura, R.; Kishi, H.; Mizukami, Y.; Mogami, K.; Kobayashi, S. Identification of the active metabolite of ticlopidine from rat in vitro metabolites. Br. J. Pharmacol., 2004, 142, 551-557. (Pubitemid 38869869)
57. Brynne, N.; Forslund, C.; Hallén, B.; Gustafsson, L.L.; Bertilsson, L. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. Br. J. Clin. Pharmacol., 1999, 48, 564-572. (Pubitemid 29454237)
58. Palmér, L.; Andersson, L.; Andersson, T.; Stenberg U. Determination of tolterodine and the 5-hydroxymethyl metabolite in plasma, serum and urine using gas chromatography-mass spectrometry. J. Pharm. Biomed. Anal., 1997, 16, 155-165. (Pubitemid 27462699)
59. Macek, J.; Ptáek, P.; Klíma, J. Determination of tolterodine and its 5-hydroxymethyl metabolite in human plasma by hydrophilic interaction liquid chromatography-tandem mass spectrometry. J. Chromatogr. B, 2009, 877, 968-974.
60. logP and TPSA were calculated by Prolog P, Pallas 3.6 program.
61. Stocker, S.L.; Franklin, M.E.; Anderson, J.M.; Pillans, P.I.; Williams, K.M.; McLachlan, A.J.; Day, R.O.; Taylor, P.J. Measurement of urinary oxypurinol by high performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B, 2010, 878, 2363-2368.
62. Sinha, V.R.; Kumar, R.V.; Bhinge, J.R. Development of a capillary electrophoresis method for the determination of allopurinol and its active metabolite oxypurinol. J. Chromatogr. B., 2003, 798, 303-308.
63. Park, J.E.; Kim, K.B.; Bae, S.K.; Moon, B.S.; Liu, K.H.; Shin, J.G. Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. Xenobiotica, 2008, 38, 1240-1251.
64. Bullen, W.W.; Miller, R.A.; Hayes, R.N. Development and validation of a high-performance liquid chromatography tandem mass spectrometry assay for atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy atorvastatin in human, dog, and rat plasma. J. Am. Soc. Mass Spectrom., 1999, 10, 55-66. (Pubitemid 34450236)
65. Muralidharan, G.; Cooper, J.K.; Hawes, E.M.; Korchinski, E.D.; Midha, K.K. Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine. Eur. J. Clin. Pharmacol., 1996, 50, 121-128. (Pubitemid 26140098)
66. http://en.wikipedia.org/wiki/Chlorpromazine
67. Boehme, C.L.; Strobel, H.W. High-performance liquid chromatographic methods for the analysis of haloperidol and chlorpromazine metabolism in vitro by purified cytochrome P450 isoforms. J. Chromatogr. B, 1998, 718, 259-266. (Pubitemid 28500000)
68. Galivan, J.H. Methotrexate uptake and metabolism in hepatic cells. (http://www.researchgrantdatabase.com/g/5R01CA025933-19/METHOTR EXATE-UPTAKE-AND-METABOLISM-IN-HEPATIC-CELLS/)
69. McCrudden, E.A.; Tett, S.E. Improved high-performance liquid chromatography determination of methotrexate and its major metabolite in plasma using a poly(styrene-divinylbenzene) column. J. Chromatogr. B, 1999, 721, 87-92. (Pubitemid 29017694)
70. Arias, C.; González, T.; Moreno, I.; Caballero, R.; Delpón, E.; Tamargo, J.; Valenzuela, C. Effects of propafenone and its main metabolite, 5-hydroxypropafenone, on HERG channels. Cardiovasc. Res., 2003, 57, 660-669. (Pubitemid 36254860)
71. Hofmann, U.; Pecia, M.; Heinkele, G.; Dilger, K.; Kroemer, H.K.; Eichelbaum, M. Determination of propafenone and its phase I and phase II metabolites in plasma and urine by high-performance liquid chromatography- electrospray ionization mass spectrometry. J. Chromatogr. B, 2000, 748, 113-123.
72. Garceau, Y.; Davis, I.; Hasegawa, J., Plasma propranolol levels in beagle dogs after administration of propranolol hemisuccinate ester. J. Pharm. Sci., 1978, 67, 1360-1363. (Pubitemid 9031051)
73. Greenblatt, D.J.; Shader, R.I.; MacLeod, S.M.; Sellers, E.M. Clinical pharmacokinetics of chlordiazepoxide. Clin. Pharmacokinet., 1978, 3, 381-894.
74. Patrick JE et al. Hydroxypropranol, Drug Metab Dispos 2002;30:430-437.
75. Johnson, J.A.; Herring, V.L.; Wolfe, M.S.; Relling, M.V. CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences. J. Pharmacol. Exp. Ther., 2000, 294, 1099-1105. (Pubitemid 30666865)
76. Pak, C.; Marriott, P.J.; Carpenter, P.D.; Amiet, R.G. Enantiomeric separation of propranolol and selected metabolites by using capillary electrophoresis with hydroxypropyl-cyclodextrin as chiral selector. J. Chromatogr. A, 1998, 793, 357-364. (Pubitemid 28044261)
77. http://www.ncbi.nlm.nih.gov/pubmed/12124303
78. Crewe, H.K.; Notley, L.M.; Wunsch, R.M.; Lennard, M.S.; Gillam, E.M. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: Formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab. Dispos., 2002, 30, 869-874. (Pubitemid 34815415)
79. Lim, C.K.; Yuan, Z.-X.; Jones, R.M.; White, I.N.H.; Smith, L.L. Identification and mechanism of formation of potentially genotoxic metabolites of tamoxifen: Study by LC-MS/MS. J. Pharm. Biomed. Anal., 1997, 15, 1335-1342. (Pubitemid 27268306)
80. Hemmateenejad, B.; Rezaei, Z.; Khabnadideh, S.; Saffari, M. A PLS-based extractive spectrophotometric method for simultaneous determination of carbamazepine and carbamazepine-10,11-epoxide in plasma and comparison with HPLC. Spectrochim. Acta, A., 2007, 68, 718-724. (Pubitemid 47499196)
81. Schipper, H.G.; Koopmans, R.P.; Nagy, J.; Butter, J.; Kager, P.A.; Van Boxtel, C.J. Effect of dose increase or cimetidine co-adminsitration on albendazole bioavailability. Am. J. Trop. Med. Hyg., 2000, 63, 270-273. (Pubitemid 32537562)
82. Marques, M.P.; Takayanagui, O.M.; Lanchote, V.L. Albendazole metabolism in patients with neurocysticercosis: Antipyrine as a multifunctional marker drug of cytochrome P450. Braz. J. Med. Biol. Res., 2002, 35, 261-269. (Pubitemid 34229072)
83. Evrard, B.; Chiap, P.; DeTullio, P.; Ghalmi, F.; Piel, G.; Van Hees, T.; Crommen, J.; Losson, B.; Delattre, L. Oral bioavailability in sheep of albendazole from a suspension and from a solution containing hydroxypropyl-cyclodextrin. J. Contr. Release, 2002, 85, 45-50. (Pubitemid 35449452)
84. Crampton, E.L.; Dickinson, W.; Haran, G.; Marchant, B.; Risdall, P.C.; Berry, P.A. The metabolism of dothiepin hydrochloride in vivo and in vitro. Br. J. Pharmacol., 1978, 64, 405P.
85. Sanchez, C.; Hyttel, Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell. Mol. Neurobiol., 1999, 19, 467-489. (Pubitemid 29283825)
86. Shibanoki, S.; Imamura, Y.; Arakawa, Y.; Ishikawa, K. Determination of dosulepin and its metabolite: Application of high-performance liquid chromatography with electrochemical detection. J. Chromatogr., 1987, 415, 365-371. (Pubitemid 17073963)